Prospective observational study on the key drug selection in advanced/recurrent EGFR mutation-positive non-small-cell lung cancer
Phase 4
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000028989
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 524
Inclusion Criteria
Not provided
Exclusion Criteria
Patients judged by the investigator to be unsuitable for the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method